J&J to Acquire Ollin for Up to USD 3.325bn for VEGF-A×Ang2 BsAb

Johnson & Johnson (J&J) has agreed to acquire Ollin Biosciences for USD 2.2 billion upfront plus up to USD 1.125 billion in regulatory and commercial milestones, and will separately secure USD 750 million in development funding from Blackstone tied to the Phase III programme for OLN324, with Blackstone eligible for milestone payments and single-digit royalties.

OLN324 originates from Innovent Biologics and is a bispecific antibody (BsAb) against VEGF-A and Ang2 for retinal diseases, designed to modulate both angiogenic pathways in a single molecule.

Early data suggest a clear edge over Roche's faricimab. In diabetic macular oedema, OLN324 improved retinal drying by 75% more at week 1 and 50% more at week 12, with nearly 90% of patients reaching fluid resolution versus 57% for faricimab, while in wet age-related macular degeneration visual gains appeared within one week and exceeded comparator effects by week 12.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details